Transthyretin Stabilizers Market Share

  • Report ID: 5491
  • Published Date: Jan 03, 2025
  • Report Format: PDF, PPT

Transthyretin Stabilizers Market Share

APAC Market Forecast

Asia Pacific industry is set to dominate majority revenue share of 40% by 2037. The adoption of telehealth and remote patient monitoring solutions is contributing to the growth of the market in the Asia-Pacific region. These technological advancements improve patient access to healthcare and facilitate the remote management of transthyretin amyloidosis. Telehealth adoption in the Asia Pacific region increased by 40% in the last two years, with a notable rise in remote consultations for rare disease management.

The integration of telehealth technologies enhances patient engagement and provides a platform for effective monitoring and management of transthyretin amyloidosis, thereby supporting the growth of the market. The market in the Asia-Pacific region is further propelled by increasing disease awareness, strategic collaborations, government support, the aging population, and the adoption of innovative healthcare technologies.

North American Market Statistics

The transthyretin stabilizers market in the North American region is projected to hold the second-largest share during the forecast period. The North American region's commitment to research and development initiatives significantly propels the market. Robust investments in scientific endeavors, including clinical trials, contribute to the advancement of innovative therapies.

The North American region's commitment to research and development initiatives significantly propels the market. Robust investments in scientific endeavors, including clinical trials, contribute to the advancement of innovative therapies. The extensive research and development ecosystem in North America not only fosters the discovery of new transthyretin stabilizers but also positions the region as a key contributor to global therapeutic innovation. The escalating prevalence of transthyretin amyloidosis in North America is a fundamental driver for the transthyretin stabilizers market. A growing understanding of the disease's spectrum and improved diagnostic capabilities contribute to a higher number of identified cases.

Research Nester
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5491
  • Published Date: Jan 03, 2025
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of transthyretin stabilizers is assessed at USD 15.23 billion.

The transthyretin stabilizers market size was over USD 14.16 billion in 2024 and is projected to reach USD 42.9 billion by 2037, growing at around 8.9% CAGR during the forecast period i.e., between 2025-2037. Increasing demand for healthcare sector will fuel the market growth.

Asia Pacific industry is set to dominate majority revenue share of 40% by 2037, impelled by surge in adoption of telehealth in the region.

The major players in the market are Pfizer Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Akcea Therapeutics, Inc., Eidos Therapeutics, Inc., FoldRx Pharmaceuticals, Inc., and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample